The approved patent is entitled “Automated Method For Assessing Cancer Risk Using Tissue Samples, And System Therefor”. This patent covers the use of an automated system for analyzing and assessing a precancerous oral lesion’s risk of progressing to oral cancer.
The awarding of the patent signals the progress that Proteocyte has made on the medical, regulatory and commercial aspects of Straticyte since its inception.
“With this US patent, we are assured that our prognostic tool for assessing the risk of developing oral cancer is protected for a number of years to come,” according to Proteocyte CEO Mark Hammar. “This should give our investors additional confidence as we continue to implement our US commercialization readiness plan.”
Dr. Anthony Morlandt, Chief Medical Officer at Proteocyte, also expresses his optimism: “This successful patent has secured intellectual property protection not only for the unique biomarkers used in oral cancer prognosis and progression, but also the artificial intelligence-powered algorithm to make accurate predictions of when a white or red patch in the mouth will become malignant.”
“In other cancers such as breast, thyroid, and melanoma, this technology has been available for many years,” Dr. Morlandt states. “Now, oral healthcare providers in the US and worldwide will finally have access to groundbreaking technology that will ultimately save lives. It’s an exciting time for many of us in this field, whether helping patients as an oral surgeon, otolaryngologist, dentist, or primary care provider.”
Proteocyte is a personalized medical diagnostics company located in MaRS Centre, Toronto, ON. Proteocyte’s product helps tackle the uncertainty surrounding oral cancer care, one of the most aggressive human cancers. The company’s oral dysplasia predictive test, Straticyte™, was developed from a panel of 811 protein biomarkers, leverages over 10 years of R&D, and is positioned to disrupt oral dysplasia and cancer care worldwide.